Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891618 | 0.85 | GPR119 (0.40) | GPR119EGFR | |
| SCHEMBL5190095 | 0.83 | GPR119 (0.37) | GPR119CHEK1EGFRSGK1TBK1 | |
| SCHEMBL5189111 | 0.81 | GPR119 (0.51) | GPR119CHEK1EGFRSGK1CYP11B2 | |
| SCHEMBL389422 | 0.81 | GPR119 (0.59) | GPR119 | |
| SCHEMBL3164490 | 0.80 | GPR119 (0.47) | GPR119 | |
| SCHEMBL6065464 | 0.69 | GPR119 (0.44) | GPR119EGFR | |
| SCHEMBL5048834 | 0.68 | GPR119 (0.54) | GPR119 | |
| SCHEMBL388757 | 0.68 | GPR119 (0.58) | GPR119 | |
| SCHEMBL5049657 | 0.66 | GPR119 (0.42) | GPR119EGFR | |
| SCHEMBL1894615 | 0.66 | GPR119 (0.62) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |